NCT02482441 - A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2015

Primary Completion Date

January 26, 2018

Study Completion Date

March 28, 2018

Conditions

Advanced Relapsed TumorsRefractory Solid Tumors

Interventions

DRUG

OMP-131R10

There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.

DRUG

FOLFIRI

Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.

Trial Locations (7)

27710

Duke University, Durham

37203

The Sarah Cannon Research Institute, Nashville

77030

M.D. Anderson Cancer Center, Houston

80045

University of Colorado Hospital Anschulz Cancer Pavilion, Aurora

95115

UCSF, San Francisco

06520-8028

Yale, New Haven

02114

Massachusetts General Hospital, Dana Farber Cancer Institute, Boston